82 related articles for article (PubMed ID: 28768306)
1. LDL-C Lowering in Prevention of Atherosclerotic Cardiovascular Disease: Another Step Forward in This Lifelong Marathon.
Nambi V; Abushamat LA
J Am Coll Cardiol; 2024 Feb; 83(6):665-668. PubMed ID: 38325991
[No Abstract] [Full Text] [Related]
2. Evolocumab use in Greece is associated with early and sustainable reductions in low-density cholesterol (LDL-C) and high persistence to therapy: Results from the Greek cohort analysis of the observational HEYMANS study.
Vlachopoulos C; Massia D; Kochiadakis G; Kolovou G; Patsilinakos S; Bridges I; Sibartie M; Dhalwani NN; Liberopoulos E; Ray KK
Hellenic J Cardiol; 2023; 74():74-76. PubMed ID: 37730147
[No Abstract] [Full Text] [Related]
3. What is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults?
Virani SS
Tex Heart Inst J; 2014 Jun; 41(3):304-5. PubMed ID: 24955047
[No Abstract] [Full Text] [Related]
4. Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?
Ballantyne CM; Minhas AMK; Orringer CE
J Am Coll Cardiol; 2023 Dec; 82(24):2262-2264. PubMed ID: 38057067
[No Abstract] [Full Text] [Related]
5. Treat to Target Confers Enhanced Low Density Lipoprotein Cholesterol Reduction Compared With a Fire and Forget Approach in Patients With Intermittent Claudication.
Sucharitkul PPJ; Safdar NZ; Bracewell B; Jain K; Coughlin PA; Bailey MA
Eur J Vasc Endovasc Surg; 2023 Sep; 66(3):440-441. PubMed ID: 37196912
[No Abstract] [Full Text] [Related]
6. Inclisiran: Government's strategy to promote cholesterol lowering drug after Brexit was "spectacular failure," says insider.
Cohen D; McCartney M
BMJ; 2024 Jan; 384():q90. PubMed ID: 38216214
[No Abstract] [Full Text] [Related]
7. Evaluation of the Inclisiran Safety in High-Risk Populations.
Jiang X; Zhang Z; Ding H
J Am Coll Cardiol; 2024 Apr; 83(13):e127. PubMed ID: 38538206
[No Abstract] [Full Text] [Related]
8. Reply: Evaluation of the Inclisiran Safety in High-Risk Populations.
Wright RS; Leiter LA; Lesogor A; Ray KK
J Am Coll Cardiol; 2024 Apr; 83(13):e129. PubMed ID: 38538207
[No Abstract] [Full Text] [Related]
9. Combination lipid therapy: could teamwork make the dream work?
Dizon S; Krasuski RA
Curr Opin Lipidol; 2021 Jun; 32(3):208-209. PubMed ID: 33900277
[No Abstract] [Full Text] [Related]
10. We don't prescribe statins to lower cholesterol: we prescribe statins to reduce vascular risk.
Tonelli M
J Am Soc Nephrol; 2015 May; 26(5):1001-3. PubMed ID: 25395431
[No Abstract] [Full Text] [Related]
11. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
Lloyd-Jones DM; Morris PB; Ballantyne CM; Birtcher KK; Daly DD; DePalma SM; Minissian MB; Orringer CE; Smith SC
J Am Coll Cardiol; 2017 Oct; 70(14):1785-1822. PubMed ID: 28886926
[TBL] [Abstract][Full Text] [Related]
12. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
Sabatine MS; Giugliano RP
JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
[No Abstract] [Full Text] [Related]
13. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
Leong D; Wu PE
CMAJ; 2019 Aug; 191(32):E894. PubMed ID: 31405836
[No Abstract] [Full Text] [Related]
14. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
15. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
Ahangari N; Ghayour Mobarhan M; Sahebkar A; Pasdar A
Ann Med; 2018 Jun; 50(4):303-311. PubMed ID: 29578362
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein cholesterol lowering treatment: the current approach.
Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC
Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792
[TBL] [Abstract][Full Text] [Related]
17. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
Lloyd-Jones DM
JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
